ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer
Sponsor: MEI Pharma, Inc.
Terminated
Company decision to wind down operations, close all clinical programs and evaluate strategic options
Other terminated trials from MEI Pharma, Inc.
- Chronic Lymphocytic Leukemia (CLL) · Phase PHASE1 · Mar 2023
- Follicular Lymphoma (FL) · Phase PHASE2 · Mar 2023
- Solid Tumors · Phase PHASE1/PHASE2 · Apr 2016
More terminations from MEI Pharma, Inc.
Listed as NCT05824559, this PHASE1 trial focuses on Colorectal Cancer and remains terminated or withdrawn. Sponsored by MEI Pharma, Inc., it has been updated 10 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Dec 2024 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2023 — May 2024 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MEI Pharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .